Pregnancies and menstrual function before and after combined radiation (RT) and chemotherapy (TVPP) for Hodgkin's disease.
The menstrual cycle, pregnancies, and offspring were evaluated before and after initial combined radiation (RT) and chemotherapy with thiotepa, vinblastine, vincristine, procarbazine, and prednisone (TVPP), in 34 women between the ages of 18 and 44 (median 26.5 years) treated for Stage II and Stage III Hodgkin's disease. The median range of follow-up is 83.1 months (range 40.5-140). After therapy 94.1% (32/34) continued to menstruate. Two of the four patients over the age of 35 ceased to menstruate. All patients under the age of 35 continued to menstruate (30/30). Age at the time of diagnosis was the only factor affecting change in menses with a significant probability (p = .001) that women greater than 30 years of age will experience some change in menstrual pattern. Seventeen pregnancies occurred in 12 women after therapy; 2 had 4 elective abortions; 10 delivered 12 children with normal physical development; 1 will deliver six months from now. Twelve of thirteen patients who wanted to become pregnant have conceived. The ability to become pregnant and deliver normal children after intensive treatment with combined radiation and chemotherapy (RT/TVPP) was comparable to the patients' pretreatment record.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000568:Amenorrhea / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003131:Combined Modality Therapy; D005260:Female; D005298:Fertility / Q000187:drug effects / Q000528:radiation effects; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008598:Menstruation / Q000187:drug effects / Q000528:radiation effects; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000209:etiology*; D011344:Procarbazine / Q000008:administration & dosage; D011878:Radiotherapy / Q000009:adverse effects*; D013852:Thiotepa / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D013852:Thiotepa; D011241:Prednisone